The initial retrospective surveys performed in New Zealand" in the early 1980s to examine the possible causes of the epidemic of asthma deaths which began to occur in the late 1970s proved useful in generating a number of hypotheses. These included: (1) an increase in the prevalence of asthma,56 (2) an increase in the severity of asthma,7 (3) changes in the provision of, and access to, primary health care,"'0 (4) direct drug toxicity, due either to individual drugs or a combination of drugs,"1 The more recent literature relating to the New Zealand epidemic has included case control studies,'14-8 retrospective dynamic cohort studies,'920 and randomised clinical trials2' and has refocused interest back on inhaled agonists as the potential cause of the epidemic. However, a closer scrutiny of the trends in both asthma mortality and morbidity from the late 1970s through to the early 1990s suggests that there were likely to have been other factors which not only contributed to the epidemic, but also to the subsequent decline in asthma mortality and morbidity. These factors will be reviewed in this paper.
Whilst there is some evidence that the prevalence of asthma increased at the time of the mortality epidemic,6 it would not have been sufficient to have accounted for the threefold increase in deaths from asthma. Since diagnostic criteria for asthma had not been standardised or validated at the time, any subsequent changes in prevalence could have been due to a change in recognition or labelling by either doctor or patient as a result of the publicity surrounding asthma in New Zealand. Certainly, international studies using the same methods of defining asthma have found no difference in the prevalence of asthma in children between New Zealand, Australia, and Canada22-24 in spite of the fact that there were 2-3 fold differences in both hospital admission and mortality rates from asthma between these countries. Furthermore, Pattemore et al25 could not find important ethnic differences in the prevalence of either asthma symptoms or levels of airway hyperresponsiveness in New Zealand to account for the 3-4 fold difference in admission rates and mortality rates between Europeans and Polynesians. Although airway hyperresponsiveness has been accepted as part of the criteria for a diagnosis of asthma in prevalence studies and is related to clinical asthma, it is not identical to it (8-15% of children who have never wheezed will show airway hyperresponsiveness and as many as 30% with typical asthma will fail to show it on several occasions26) and therefore cannot reliably or precisely separate asthmatic from non-asthmatic subjects. In addition, airway hyperresponsiveness is more usually measured at one point in time in prevalence studies whilst questionnaires extract information on symptoms experienced over the preceding year or years. Even detailed history taking (on which the clinical diagnosis of asthma largely depends) lacks objectivity. There has been a tendency recently to accept the prescription of asthma medication as fulfilling a diagnosis of asthma.2728 However, asthma medications are often prescribed for an acute bronchitis which may also cause symptoms which are difficult to distinguish from those of asthma in a questionnaire survey. Until a clear internationally accepted definition for asthma was developed by Toelle et al29 the wide variety of study methods made it difficult to be certain about the true prevalence ofasthma and whether reported increases were real or apparent, both in New Zealand6 and elsewhere.'03' The recent finding by Peat et al'2 of a significant increase in airway hyperresponsiveness in two 8-10 year old populations during two different time periods (1982 and 1992) therefore remains the strongest argument for an increase in prevalence, although these results need to be reproduced in other studies, in other countries (and in older patients), and preferably in populations followed longitudinally.
AN INCREASE IN SEVERITY
Changes in mortality and morbidity rates may result from a change in either baseline asthma (fig 1) which was temporally associated with a sudden increase in asthma admission and mortality rates. As Rea et at'4 have shown, psychosocial problems (of which recent unemployment was a component), when measured retrospectively from hospital records or relatives, were independently associated with an increased risk of death from asthma, RR= 3-5 (95% CI 1 04 to 13-7) when patients dying of asthma were compared with hospital controls (and would have been expected to have been of greater significance if the control group had been made up from asthmatics in the community since psychosocial problems are likely to be associated with asthma morbidity36 as well as mortality). Therefore, although psychological and social factors are likely to be important, there have been few systematic data collected in New Zealand or internationally to evaluate the interrelationship between psychosocial and other risk factors for death.
At the beginning of the epidemic mortality rates were already twice as high in disadvantaged neighbourhoods as in middle class or advantaged areas in New Zealand.371-owever, the subsequent increase in deaths occurred mainly in the middle and lower socioeconomic areas (fig 2) , the increase in mortality rate in lower socioeconomic class areas being 2-3 times that of higher socioeconomic areas. A lack of accessibility to primary health care for financial, social, and cultural reasons, in association with poor organisation of after hours care, might explain why over 50% ofpatients who died from asthma had not sought medical help during their final attack, why there was an increased frequency of deaths and intensive care unit admissions on Sunday,"8 and why discontinuity of medical care -an independent risk factor for death ' found more consistently in New Zealand where 50% had not called for medical help until they were in extremis. The consistent theme throughout all of these studies was the underutilisation of primary health care, particularly after hours where organisation barriers to community care existed along with financial barriers, presumably as a result of an increase in cost against a background of social and economic decline in the 1970s.
Implementation of changes to asthma management in New Zealand Despite the problem of increasing financial barriers to primary health care and the subsequent introduction of part charges on prescriptions, a number of initiatives were introduced during the 1980s to help to reduce mortality from asthma:
(1) Development of an asthma task force. In response to the "epidemic" of asthma deaths the New Zealand Medical Research Council set up an asthma task force. Although studies performed did not identify a single cause for the epidemic, asthma management policies were implemented to help to correct the multiple deficiences identified. (2) National education campaigns. These were directed separately at the lay public, patients, and medical community. (fig 7) . Furthermore, the marked increase in intensive care unit (ICU) admissions in Auckland (without a change in admission criteria for the ICU38), and the continuing increase in first admissions nationally (fig 5) , suggested that the number of severe attacks occurring in the community was rising at the time when mortality was declining. We believe that the reduction in mortality during the 1980s is best explained by earlier intervention in the management of severe attacks with an increase in the appropriate utilisation of hospital based care. This was not unexpected as the initiatives introduced at the 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 
Figure 8 Age standardised asthma admission rates and emergency department "4 hours" attendance rates for sickness in New Zealand's four main centres in 1981.
-3.0 higher emergency department use and admission rate for asthma by Maoris and Pacific o Islanders was more likely to be due to differo ences in availability of community based med--2.5 : ical care, a lack of self management skills and Q preventive medications, and socioeconomic , factors than to differences in baseline severity.9 c For the major hospitals serving New Zealand's -2.0°-four main centres there was a correlation between the attendance at emergency departv ments after hours for any sickness (age stand-< ardised) and hospital admissions with asthma 1.5 (age standardised) (R=0-96, p=OO01) (fig  8) . The sociodemographic characteristics of patients attending the emergency department with sickness are identical to those of asthmatic patients.864 Differences in admission rates be-)er tween hospitals in New Zealand are therefore likely to reflect the sociodemographic characteristics of the surrounding community and the organisation of after hours medical care. If med at such characteristics can explain twofold differttacks. ences in admission rates within New Zealand, d have then the same reasoning may explain the twoto im-fold differences between admission rates in ute at-New Zealand and other western countries65 ty such without the need to evoke differences in either rtment prevalence or severity of asthma.
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More recently the situation has changed further. Since 1990 there has been a dramatic fall here is in all measures of asthma morbidity: a 70% everity, reduction in ICU admissions in Auckland th care (New Zealand's largest city), a 34% reduction valuate in hospital admissions and use of acute amt study bulance services nationally, and a 25% re-JK the duction in emergency department use in Idhood Auckland. The asthma mortality rate, which nds in had continued to fall gradually through the !s, par-1980s, has taken a further steep reduction in iges in 1990. These recent changes suggest that there ar ob-has now been a reduction in the baseline sed have verity of asthma or in the frequency of severe re been attacks. Recent publications have suggested -re was that this recent reduction in mortality is due to pposed the withdrawal of inhaled fenoterol.4066 Inhaled hen we fenoterol was effectively withdrawn from the [ier use market in late 1989 as a result of the caserement control studies'5-17 which had shown an astal ad-sociation between prescribed inhaled fenoterol .10 The and mortality. Subsequent studies performed by ourselves'920 and others48 suggest that the association was due to confounding by severity ]ton) rather than a causal one, and that inhaled fenoterol was channelled for use by patients with more severe asthma.6768
The question still remains, however, whether inhaled 3 agonists as a class are capable of increasing asthma severity. Several studies have provided evidence that regular administration of 3 agonists might be associated with some deterioration of asthma,2'6970 but the results have been conflicting.71-73 Sears et 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 Year (fig 5) , three years before the fenoterol studies were first published. High dose inhaled steroids were made available to general practitioners subsequently in 1987 and first admissions with asthma began to fall two years later. The prescription of these drugs indicates an increasing use of "disease modifying" drugs and may also reflect heightened awareness of, and general improvements in, asthma management -that is, they may be a marker of good general care as is suggested in our study of peak flow meter usage. 59 Despite the fact that inhaled steroids would have been channelled for use in the most severe subgroups of asthmatic patients and that there was relatively little use of high dose inhaled steroids at the time the Wellington research group's studies were undertaken,'5"'7 none of the studies showed a positive association between inhaled steroids and mortality. The Saskatchewan study79 actually suggests that higher dose inhaled steroids are protective of mortality or severe life threatening attacks. Clinical experience in New Zealand suggests that it has been the increased use of appropriate doses of inhaled steroid80 and associated strategies which have had the greatest impact on morbidity. Although there is a paucity of dose-response data in the literature, it is acknowledged that escalating doses of inhaled steroids lead to an improvement in asthma control and allow reduction or withdrawal of systemic steroid therapy. 8 
